Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer

National Institute for Health and Clinical Excellence
Record ID 32006000888
English
Authors' objectives:

The aim of this review is to provide guidance on the use of trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer.

Authors' recommendations: 1 Guidance 1.1 Trastuzumab, given at 3-week intervals for 1 year or until disease recurrence (whichever is the shorter period), is recommended as a treatment option for women with early-stage HER2-positive breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable). 1.2 Cardiac function should be assessed prior to the commencement of therapy and trastuzumab treatment should not be offered to women who have a left ventricular ejection fraction (LVEF) of 55% or less, or who have any of the following: - a history of documented congestive heart failure - high-risk uncontrolled arrhythmias - angina pectoris requiring medication - clinically significant valvular disease - evidence of transmural infarction on electrocardiograph (ECG) - poorly controlled hypertension. 1.3 Cardiac functional assessments should be repeated every 3 months during trastuzumab treatment. If the LVEF drops by 10% from baseline and to below 50% then trastuzumab treatment should be suspended. A decision to resume trastuzumab therapy should be based on a further cardiac assessment and a fully informed discussion of the risks and benefits between the individual patient and their clinician.
Authors' methods: Systematic review
Details
Project Status: Completed
Year Published: 2006
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England
MeSH Terms
  • Chemotherapy, Adjuvant
  • Receptor, ErbB-2
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Breast Neoplasms
Contact
Organisation Name: National Institute for Health and Care Excellence
Contact Address: Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name: nice@nice.nhs.uk
Contact Email: nice@nice.nhs.uk
Copyright: National Institute for Health and Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.